Έρευνα & Κλινικές Μελέτες
Συμβάλλουμε ενεργά στην εξέλιξη της ιατρικής επιστήμης μέσω έρευνας, καινοτομίας και συνεργασιών.
Κλινικές Μελέτες
43 διαθέσιμες μελέτες
SUNRAY-01/J3M-MC-JZQB
«SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression»
ΕΝΕΡΓΟ RECRUITMENT
Δείτε περισσότερα
SUNRAY-02/J3M-MC-JZQH
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
ΑΝΑΜΕΝΕΤΑΙ ΝΑ ΞΕΚΙΝΗΣΕΙ
Δείτε περισσότερα
C4391024
«AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3) »
ΕΝΕΡΓΟ RECRUITMENT
Δείτε περισσότερα
JADE/221530
«A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma»
ΕΝΕΡΓΟ RECRUITMENT
Δείτε περισσότερα
POLQi /219590
«A PHASE 1/2 FIRST-TIME-IN-HUMAN, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION STUDY OF THE ORAL DNA POLYMERASE THETA INHIBITOR (POLQI) GSK4524101 AND THE PARP INHIBITOR (PARPI) NIRAPARIB IN ADULT PARTICIPANTS WITH SOLID TUMORS»
ΑΝΑΜΕΝΕΤΑΙ ΝΑ ΞΕΚΙΝΗΣΕΙ
Δείτε περισσότερα
223674
«A Phase 3, Multicentre, Randomized, Open-label Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), versus Topotecan in Subjects with Relapsed Small Cell Lung Cancer (SCLC)»
ΑΝΑΜΕΝΕΤΑΙ ΝΑ ΞΕΚΙΝΗΣΕΙ
Δείτε περισσότερα
CAMBRIA-2 / D8535C00001
«A Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease»
ΕΝΕΡΓΟ RECRUITMENT
Δείτε περισσότερα
TROPION / D926XC00001
«A PHASE 3 OPEN-LABEL, RANDOMISED STUDY OF DATOPOTAMAB DERUXTECAN (DATO-DXD) WITH or WITHOUT DURVALUMAB VERSUS INVESTIGATOR’S CHOICE OF THERAPY IN PATIENTS WITH STAGE I-III TRIPLE-NEGATIVE BREAST CANCER WHO HAVE RESIDUAL INVASIVE DISEASE IN THE BREAST AND/OR AXILLARY LYMPH NODES AT SURGICAL RESECTION FOLLOWING NEOADJUVANT SYSTEMIC THERAPY (TROPION-BREAST03) »
ΜΗ ΕΝΕΡΓΟ RECRUITMENT
Δείτε περισσότερα
DELLPHI-306 (20230016)
«A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects with Limited-Stage Small-Cell Lung Cancer(LS-SCLC) who Have Not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306) »
ΕΝΕΡΓΟ RECRUITMENT
Δείτε περισσότερα
CODEBREAK 301 (20210081)
«Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI with or Without Bevacizumab-awwb for Treatment-naïve Subjects with Metastatic Colorectal Cancer with KRAS p. G12C Mutation»
ΕΝΕΡΓΟ RECRUITMENT
Δείτε περισσότερα
DELLPHI-304 (20210004)
«A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF TARLATAMAB COMPARED WITH STANDARD OF CARE IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER AFTER PLATINUM-BASED FIRST-LINE CHEMOTHERAPY (DELLPHI-304) »
ΜΗ ΕΝΕΡΓΟ RECRUITMENT
Δείτε περισσότερα
FORTITUDE (20210096)
«A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression (FORTITUDE-101) »
ΜΗ ΕΝΕΡΓΟ RECRUITMENT
Δείτε περισσότερα